Odyssey Therapeutics
ODTX
17.24
-0.84
-4.65%
Odyssey Therapeutics
US · ODTX
#3348 by market cap
Listed 2026
17.24
-0.84
-4.65%
Live - 5344 symbols - heartbeat 139s ago
· 2026-10-08 09:58
After-hours
18.08
0.00%
- Market cap
- 828.53M
- P/E (TTM)i
- -5.16
- P/Bi
- 1.97
- EPSi
- -3.15
- Div yieldi
- 0.00%
- 52W posi
- 15%
Reader sentiment
Are you bullish or bearish on ODTX?
Anonymous reader poll. Unscientific, not investment advice.
About Odyssey Therapeutics
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
- CEO
- Dr. Gary D. Glick, PhD
- Employees
- 151
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- odysseytx.com
Company profile
- Exchange
- US
- Symbol
- ODTX
- Market-cap rank
- #3348
- Listing date
- 2026-05-08
- Market cap
- 828.53M
- Float cap
- 267.22M
- Shares out
- 48.06M
- Float shares
- 15.50M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-10-08 09:58:49 · For reference only, not investment advice and not tailored to your situation.